Mylan Pharmaceuticals, Inc. v. United States Food & Drug Administration Case Brief
Complete case briefs with LSD+
Every LSD.Law brief pairs a full IRAC analysis with opinion summaries at three levels of depth, written by a team of Harvard Law and MIT graduates - a quick synopsis when you are pressed for time, the complete reasoning when you need to go deep.
Adaptive Case Views
Toggle between Flash, Standard, and Expanded. Get what you need, when you need it.
Exam-Ready IRAC Format
We deliver the precise structure professors look for in exam answers.
Complex Cases, Clarified
We break down dense legal reasoning into something digestible, helping you grasp core concepts.
Case Brief Summary & Legal Analysis
tl;dr: FDA denied Mylan’s petition to block an “authorized generic” during Mylan’s 180-day exclusivity period. The court affirmed, finding the statute unambiguous and not granting FDA such power.
Legal Significance: Reinforces FDA’s interpretation of the Hatch-Waxman Act, clarifying that the 180-day exclusivity for first generic filers does not bar competition from “authorized generics” marketed by brand-name drug companies.
Mylan Pharmaceuticals, Inc. v. United States Food & Drug Administration Law School Study Guide
Use this case brief structure for your own legal analysis. Focus on the IRAC methodology to excel in law school exams and cold calls.
Case Facts & Court Holding
Key Facts & Case Background
Mylan Pharmaceuticals, Inc. (Mylan) received FDA approval for a generic version of Macrobid and was entitled to a 180-day market exclusivity period under the Hatch-Waxman Act, 21 U.S.C. § 355(j)(5)(B)(iv). Concurrently, Procter & Gamble, the brand-name drug (NDA) holder, licensed a third party, Watson Pharmaceuticals, to sell an “authorized generic” version of Macrobid. Mylan petitioned the FDA, arguing that the authorized generic could not be sold during its 180-day exclusivity period. The FDA denied Mylan’s petition, concluding the Act did not prohibit an NDA holder from marketing its own approved drug, including through an authorized generic, during this period. The FDA reasoned that the exclusivity provision only restricts subsequent Abbreviated New Drug Application (ANDA) applicants, not drugs marketed under an existing New Drug Application (NDA). Mylan sued the FDA under the Administrative Procedure Act (APA), alleging the denial was arbitrary, capricious, or contrary to law. The district court dismissed Mylan’s complaint.
Court Holding & Legal Precedent
Issue: Did the Food and Drug Administration lawfully interpret 21 U.S.C. § 355(j)(5)(B)(iv) of the Hatch-Waxman Act as not granting it the authority to prohibit the marketing of an “authorized generic” drug by an NDA holder during the 180-day exclusivity period afforded to the first generic ANDA filer?
Yes, the FDA’s interpretation was lawful. The court affirmed the dismissal, holding Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Du
IRAC Legal Analysis
About IRAC analysis
IRAC (Issue, Rule, Analysis, Conclusion) is the structure professors expect in exam answers. Each LSD.Law brief states the issue, the governing rule with citations, the court's application of that rule, and the conclusion - the same reasoning pattern you will use on exams and in practice.
Legal Issue
Did the Food and Drug Administration lawfully interpret 21 U.S.C. § 355(j)(5)(B)(iv) of the Hatch-Waxman Act as not granting it the authority to prohibit the marketing of an “authorized generic” drug by an NDA holder during the 180-day exclusivity period afforded to the first generic ANDA filer?
Conclusion
This case affirms the FDA's narrow interpretation of the 180-day generic drug Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit
Legal Rule
Agency interpretations of statutes they administer are reviewed under the *Chevron* framework. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deseru
Legal Analysis
The court applied the *Chevron* framework to review the FDA's interpretation of Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cil
Flash-to-Full Case Opinions
Flash Summary
- The FDA lacks authority under 21 U.S.C. § 355(j)(5)(B)(iv) to block